Brief: Medicenna Announces New Data Providing Preliminary Evidence Of MDNA11's Anti-Cancer Activity In Phase 1/2 Study
27/07/2022 13:30
July 27 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES NEW CLINICAL DATA PROVIDING
PRELIMINARY
EVIDENCE OF MDNA11'S SINGLE AGENT ANTI-CANCER ACTIVITY IN PHASE
1/2 ABILITY STUDY
* MEDICENNA THERAPEUTICS CORP - TUMOR CONTROL WAS ACHIEVED
IN FOUR
OF TEN EVALUABLE PATIENTS
Source text for Eikon: ID:nGNX94YGJR
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results